Type 2 Diabetes

ACP Defends Higher Blood Glucose Targets for Type 2 Diabetes

ACP responds to criticism from the ADA, the Endocrine Society, the AACE, and the AADE of guidance that clinicians should aim to achieve an HbA1c ...

Case for Continuous Glucose Monitoring in Youth-Onset Type 2 Diabetes

An increasing number of studies support the use of continuous glucose monitoring in adult patients with T2D, and the observed benefits are likely to extend ...

Ask the Experts: Dr Goyal on SGLT2 Inhibitors

Dr Goyal from NYU Langone Health in New York City talks about SGLT2 inhibitors in the treatment of type 2 diabetes.

Addressing Psychological Insulin Resistance in Patients With Diabetes

Learn about strategies to reduce a patient's reluctance to initiate insulin therapy, a phenomenon called psychological insulin resistance.

Managing Type 2 Diabetes: The Impact of Secure Patient-Provider Messaging

Secure messaging presents an opportunity for patients and healthcare providers to collaborate on self-management issues like glycemic control, diet, and exercise.

In-Hospital Tramadol Use Increases Hypoglycemia Risk in T1D, T2D

Results indicate that blood glucose monitoring should be conducted in hospitalized patients with diabetes.

Type 2 Diabetes and Antidepressant Drug Use: Is There a Causal Link?

Updated meta-analysis confirms the association between antidepressant drug (AD) use and incident diabetes. Future studies should be aimed at evaluating the effect of single AD ...

Video

Latest Headlines

Availability and Affordability of Diabetes Medication Worldwide

Availability and Affordability of Diabetes Medication Worldwide

The affordability and availability of diabetes medications across multiple regions of the word were examined, along with the effects on the use of medications.

Intensive Blood Pressure Therapy Lowers Cardiovascular Risk in Diabetes

Intensive Blood Pressure Therapy Lowers Cardiovascular Risk in Diabetes

Intensive blood pressure therapy is associated with a significantly lower risk for serious cardiovascular events in the adults with diabetes.

Higher Aldosterone Levels Tied to Incident Type 2 Diabetes Risk

Higher Aldosterone Levels Tied to Incident Type 2 Diabetes Risk

Higher levels of aldosterone are associated with insulin resistance and incident type 2 diabetes among multiethnic individuals.

Early Treatment Intensification and Faster Glycemic Control in T2D

Early Treatment Intensification and Faster Glycemic Control in T2D

Individuals with type 2 diabetes intensifying within 12 months of the index date had a significantly shorter median time from intensification to glycemic control.

Comparing Second-Generation Basal Insulin Analogs for Type 2 Diabetes

Comparing Second-Generation Basal Insulin Analogs for Type 2 Diabetes

Researchers concluded noninferiority between two basal insulin analogs after comparing safety and efficacy end points.

Comparing Antidiabetic Drug Classes for Risk of Heart Failure

Comparing Antidiabetic Drug Classes for Risk of Heart Failure

The authors searched for randomized placebo-controlled trials (December 1, 2008 to November 24, 2017) involving 3 pharmacologic classes of antidiabetic medications to compare the effects of these agents on the risk of hospitalization for HF in T2DM patients.

Widespread Statin Use Not Recommended in Old, Very Old

Widespread Statin Use Not Recommended in Old, Very Old

Statin use is not associated with reduced risk of atherosclerotic cardiovascular disease or all-cause mortality among older adults without type 2 diabetes.

Trends in Cardiovascular Deaths for US Adults With and Without Diabetes

Trends in Cardiovascular Deaths for US Adults With and Without Diabetes

Investigators used data from the National Health Interview Survey and follow-up mortality data to estimate trends and disparities in CVD.

Comparing Efficacies of Second-Line Treatments in Type 2 Diabetes

Comparing Efficacies of Second-Line Treatments in Type 2 Diabetes

Researchers conducted a retrospective analysis to determine whether second-line treatment options sulfonylureas, DPP-4 inhibitors, and thiazolidinediones were associated with reduced HbA1c levels.

Polypharmacy Therapy for Schizophrenia Increases Risk for Type 2 Diabetes

Polypharmacy Therapy for Schizophrenia Increases Risk for Type 2 Diabetes

Investigators aimed to assess the effect of psychotropic medications, BMI, duration of schizophrenia, number of hospitalizations, and physical activity on the risk for T2D.

Sign Up for Free e-Newsletters



CME Focus